Editorial: Type III interferons: Emerging roles beyond antiviral barrier defense

Front Immunol. 2022 Sep 14:13:1030812. doi: 10.3389/fimmu.2022.1030812. eCollection 2022.

Steeve Boulant¹, Adriana Forero^{2

3

4}, Deanna M Santer⁵, Achille Broggi⁶

¹ Department of Molecular Genetics & Microbiology University of Florida, College of Medicine, Gainesville, FL, United States.
² Department of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH, United States.
³ Infectious Diseases Institute, The Ohio State University, Columbus, OH, United States.
⁴ The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States.
⁵ Department of Immunology, University of Manitoba, Winnipeg, MB, Canada.
⁶ Aix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), Marseille, France.

No abstract available

Keywords: IBD; IFN-lambda; IFN-λ4; antiviral; infection; interferon; mucosae; vaccine.

Publication types